Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Lessened by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC lowered its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 11.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,784 shares of the company’s stock after selling 20,000 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.10% of Xeris Biopharma worth $518,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of XERS. R Squared Ltd purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at $42,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma in the third quarter valued at $44,000. Raymond James Financial Inc. purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth $45,000. Sunpointe LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth $71,000. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after acquiring an additional 5,500 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $4.82 on Friday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $4.90. The stock’s 50-day moving average is $3.68 and its two-hundred day moving average is $3.31. The firm has a market cap of $741.99 million, a P/E ratio of -10.71 and a beta of 2.32.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Leerink Partners increased their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $5.92.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.